These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38773427)

  • 1. Effect of novel anti-tumor and anti-angiogenesis drug taurolactone on angiogenic factor AGGF1 and angiogenesis mimicry in patients with hepatocellular carcinoma.
    Liu S; Wei Y; Nie L; Tang Z; Lu Q; Liang Q
    BMC Cancer; 2024 May; 24(1):614. PubMed ID: 38773427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of AGGF1 is correlated with angiogenesis and poor prognosis of hepatocellular carcinoma.
    Wang W; Li GY; Zhu JY; Huang DB; Zhou HC; Zhong W; Ji CS
    Med Oncol; 2015 Apr; 32(4):131. PubMed ID: 25796501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway.
    Li W; Fu Q; Man W; Guo H; Yang P
    Eur J Pharmacol; 2019 Apr; 849():106-114. PubMed ID: 30710550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1) Acts as Diagnostic Biomarker and Adverse Prognostic Factor of Hepatocellular Carcinoma (HCC): Evidence from Bioinformatic Analysis.
    Wang W; Zhu G; Lai S; Guo Y; Yin X; Chen D; Wen L
    Med Sci Monit; 2020 Feb; 26():e919896. PubMed ID: 32090983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.
    Wada H; Nagano H; Yamamoto H; Yang Y; Kondo M; Ota H; Nakamura M; Yoshioka S; Kato H; Damdinsuren B; Tang D; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Sakon M; Dono K; Wakasa K; Monden M
    Liver Int; 2006 May; 26(4):414-23. PubMed ID: 16629644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
    Hu C; Li W; Tian F; Jiang K; Liu X; Cen J; He Q; Qiu Z; Kienast Y; Wang Z; Zhang H; Ji Y; Hu J; Hui L
    J Hepatol; 2018 Mar; 68(3):465-475. PubMed ID: 29113912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
    Zheng N; Zhang S; Wu W; Zhang N; Wang J
    Pharmacol Res; 2021 Apr; 166():105507. PubMed ID: 33610718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
    Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
    Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
    Kuczynski EA; Yin M; Bar-Zion A; Lee CR; Butz H; Man S; Daley F; Vermeulen PB; Yousef GM; Foster FS; Reynolds AR; Kerbel RS
    J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27059374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Nasr M; Selima E; Hamed O; Kazem A
    Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of angiogenic factor AGGF1 is an independent prognostic factor for hepatocellular carcinoma.
    Tu J; Ying X; Zhang D; Weng Q; Mao W; Chen L; Wu X; Tu C; Ji J; Huang Y
    Oncotarget; 2017 Dec; 8(67):111623-111630. PubMed ID: 29340079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
    Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epigallocatechin gallate derivative Y
    Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
    J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.
    Wei Y; Yang Q; Zhang Y; Zhao T; Liu X; Zhong J; Ma J; Chen Y; Zhao C; Li J
    Oncotarget; 2017 Feb; 8(9):15230-15241. PubMed ID: 28122355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.
    Carpizo DR; Gensure RH; Yu X; Gendel VM; Greene SJ; Moore DF; Jabbour SK; Nosher JL
    J Vasc Interv Radiol; 2014 Feb; 25(2):297-306.e1. PubMed ID: 24360887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
    Zhao ZC; Zheng SS; Wan YL; Jia CK; Xie HY
    Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):529-36. PubMed ID: 14627514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
    El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N
    Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?
    Moon WS; Rhyu KH; Kang MJ; Lee DG; Yu HC; Yeum JH; Koh GY; Tarnawski AS
    Mod Pathol; 2003 Jun; 16(6):552-7. PubMed ID: 12808060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.